F8 and hemophilia A: The main objective of the study was to evaluate the effectiveness of prophylaxis with recombinant FVIII Fc fusion protein in improving the perceived quality of life in adult patients with severe hemophilia A. The secondary objective was to analyze the effectiveness of this treatment with rFVIIIFc on adherence to prophylactic treatment in these patients, as well for reducing fear of movement, after a 12-month study period.